Data Insights

FS-222 by F-star Therapeutics for Melanoma: Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Melanoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Melanoma

Data Insights

FS-222 by F-star Therapeutics for Ovarian Cancer: Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Ovarian Cancer

Data Insights

FS-222 by F-star Therapeutics for Colorectal Cancer: Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Colorectal Cancer

Data Insights

FS-222 by F-star Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Non-Small Cell Lung Cancer

Data Insights

FS-222 by F-star Therapeutics for Malignant Mesothelioma: Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Malignant Mesothelioma

Data Insights

FS-222 by F-star Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

FS-222 is under clinical development by F-star Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - FS-222 in Triple-Negative Breast Cancer (TNBC)